Table: q1_q4_2023_prescription_drugs_intro_to_market , manufacturer_name like L*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	drug_category	drug_category_source	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
La Jolla Pharmaceutical Company	68547011110	Xacduro For IV Soln 1-1 GM, 3 Each, Unit-Dose, Box	Brand	FDA	2023-08-15	475.0000	In support of the launch of XACDURO, La Jolla is highly focused on HCP promotion to HCPs in Hospital Settings. This promotion will begin on September 18, 2023. There will be no Direct-to-Consumer advertising. We engaged a trusted, independent pharmaceutical compliance consulting firm to conduct pricing primary market research with target HCPs. This included value-based pricing surveys and HCP feedback which indicated an acceptable price range for XACDURO on-label usage based on average patient day of therapy. This comprehensive evaluation included other life-saving antibiotics and we compared that analysis with pharmacoeconomics to determine the ultimate value of XACDURO.	None	19000	None	1	None	None	None	None	None	None